Suppr超能文献

肾移植治疗过敏性紫癜肾炎后复发和移植物丢失:一项多中心分析。

Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis.

机构信息

Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

出版信息

Clin J Am Soc Nephrol. 2011 Jul;6(7):1768-72. doi: 10.2215/CJN.00520111.

Abstract

BACKGROUND AND OBJECTIVES

The actuarial risk at 5 years for clinical recurrence of Henoch-Schönlein purpura nephritis (HSPN) and graft loss caused by recurrence of -HSPN after renal transplantation was reported in 1994 to be as high as 35% and 11%, respectively. The aim of this study is to re-evaluate, in a large cohort of patients with a long-term follow-up, whether these rates have changed.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients from six transplant centers in Belgium and France with strict diagnostic criteria of HSPN and a potential post transplant follow-up of ≥3 years were included.

RESULTS

Forty-three patients were included. Patient survival is excellent: 98%, 95%, and 95% at 5, 10, and 15 years, respectively. Overall graft survival rates were 84%, 66%, and 56% at 5, 10, and 15 years, respectively. Clinical recurrence in a first kidney transplant occurred in five patients. Three patients lost their first graft due to HSPN recurrence 19 to 96 months after transplantation, two of whom had systemic signs of the illness. Actuarial risk for clinical recurrence in a first graft is 2.5% and 11.5% at 5 and 10 years, respectively. Actuarial risk for graft loss caused by recurrence in a first graft is 2.5% and 7.5% at 5 and 10 years, respectively. Severity of the disease at presentation and type of immunosuppression after transplantation did not affect recurrence.

CONCLUSIONS

We found that recurrence rates of HSPN after transplantation are lower than previously reported. The actuarial risk of graft loss from recurrence in a first graft is 7.5% at 10 years.

摘要

背景和目的

1994 年报道,在肾移植后由 Henoch-Schönlein 紫癜肾炎(HSPN)复发引起的临床复发和移植物丢失的 5 年累积风险分别高达 35%和 11%。本研究的目的是在长期随访的大样本患者中重新评估这些比率是否发生了变化。

设计、设置、参与者和测量:本研究纳入了来自比利时和法国六个移植中心的符合 HSPN 严格诊断标准且具有潜在移植后随访时间≥3 年的患者。

结果

共纳入 43 例患者。患者存活率极高:分别为 98%、95%和 95%,在 5、10 和 15 年时。整体移植物存活率分别为 84%、66%和 56%,在 5、10 和 15 年时。在首次肾移植中发生了 5 例临床复发。有 3 例患者由于 HSPN 复发而在移植后 19 至 96 个月失去了首次移植物,其中 2 例患者有全身性疾病的体征。首次移植物临床复发的累积风险分别为 2.5%和 11.5%,在 5 年和 10 年时。首次移植物因复发导致移植物丢失的累积风险分别为 2.5%和 7.5%,在 5 年和 10 年时。疾病发作时的严重程度和移植后免疫抑制的类型并未影响复发。

结论

我们发现,HSPN 在移植后复发的比率低于之前报道的比率。首次移植物因复发导致移植物丢失的 10 年累积风险为 7.5%。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验